Sionna Therapeutics Inc (SION)

$24.39 +0.65 (2.74%)
Market Cap 1.08B
Revenue (ttm) 0.00
Net Income (ttm) -61.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 184,700
Avg Vol 208,252
Day's Range N/A - N/A
Shares Out 44.14M
Stochastic %K 88%
Beta N/A
Analysts Strong Sell
Price Target $38.50

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 819 2020
Address:
21 Hickory Drive, Suite 500, Waltham, United States
Doozio
Doozio Aug. 20 at 3:33 PM
$SION sneaking out on the DLO
0 · Reply
Doozio
Doozio Aug. 18 at 11:10 PM
$SION moar hidden DRUG 💎s during 🐒🍌🧠⏰♾️?
0 · Reply
smartkarma
smartkarma Aug. 13 at 12:03 PM
$SION | Sionna Therapeutics (SION) Six Month Summary: Hot Start, Cold Reality, and a Strong Spring Rebound "​Sionna Therapeutics' successful IPO sees strong market debut with 38.9% premium, fueled by positive Phase I data for Metsera." - IPO Boutique (IPO Boutique) Read more: https://www.smartkarma.com/insights/sionna-therapeutics-sion-six-month-summary-hot-start-cold-reality-and-a-strong-spring-rebound
0 · Reply
DeadManJoaquin
DeadManJoaquin Jul. 25 at 2:31 PM
$SION anytime you see a stock that is owned by both Baker Brothers and Perceptive Advisors it's worth paying some attention to. There are only three at this point in time. The other two have both printed cash, $VRNA and $INSM. This one is very early, phase one and phase 2. Still, probably worth keeping on your radar. The TAM is massive and mgt looks pretty solid.
3 · Reply
Latest News on SION
Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 12 days ago

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Jun 6, 2025, 11:00 AM EDT - 2 months ago

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Jun 4, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

May 22, 2025, 7:00 AM EDT - 3 months ago

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

Sionna Therapeutics Reports First Quarter 2025 Financial Results

May 12, 2025, 7:00 AM EDT - 3 months ago

Sionna Therapeutics Reports First Quarter 2025 Financial Results

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 30, 2025, 7:00 AM EDT - 4 months ago

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 6 months ago

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 10, 2025, 4:03 PM EST - 6 months ago

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Feb 8, 2025, 2:30 AM EST - 7 months ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AARD AGH EPWK FBGL HCAI KRMN NPB

Sionna Therapeutics Prices Upsized Initial Public Offering

Feb 6, 2025, 7:51 PM EST - 7 months ago

Sionna Therapeutics Prices Upsized Initial Public Offering

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 7 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE MTSR ODTX ODYS

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Jan 24, 2025, 1:45 PM EST - 7 months ago

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO

Jan 17, 2025, 7:07 PM EST - 7 months ago

Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO

Sionna Therapeutics IPO Registration Document (S-1)

Jan 17, 2025, 5:00 PM EST - 7 months ago

Sionna Therapeutics IPO Registration Document (S-1)

Doozio
Doozio Aug. 20 at 3:33 PM
$SION sneaking out on the DLO
0 · Reply
Doozio
Doozio Aug. 18 at 11:10 PM
$SION moar hidden DRUG 💎s during 🐒🍌🧠⏰♾️?
0 · Reply
smartkarma
smartkarma Aug. 13 at 12:03 PM
$SION | Sionna Therapeutics (SION) Six Month Summary: Hot Start, Cold Reality, and a Strong Spring Rebound "​Sionna Therapeutics' successful IPO sees strong market debut with 38.9% premium, fueled by positive Phase I data for Metsera." - IPO Boutique (IPO Boutique) Read more: https://www.smartkarma.com/insights/sionna-therapeutics-sion-six-month-summary-hot-start-cold-reality-and-a-strong-spring-rebound
0 · Reply
DeadManJoaquin
DeadManJoaquin Jul. 25 at 2:31 PM
$SION anytime you see a stock that is owned by both Baker Brothers and Perceptive Advisors it's worth paying some attention to. There are only three at this point in time. The other two have both printed cash, $VRNA and $INSM. This one is very early, phase one and phase 2. Still, probably worth keeping on your radar. The TAM is massive and mgt looks pretty solid.
3 · Reply